ojrdrtОнкологический журнал: лучевая диагностика, лучевая терапияJournal of oncology: diagnostic radiology and radiotherapy2587-75932713-167XНЕКОММЕРЧЕСКОЕ ПАРТНЕРСТВО «ОБЩЕСТВО ИНТЕРВЕНЦИОННЫХ ОНКОРАДИОЛОГОВ»10.37174/2587-7593-2021-4-1-53-64ojrdrt-157Research ArticleКОМБИНИРОВАННЫЕ МЕТОДЫ ДИАГНОСТИКИ И ЛЕЧЕНИЯCOMBINED METHODS OF DIAGNOSTICS AND TREATMENTОбзор классификаций промежуточной стадии гепатоцеллюлярной карциномыIntermediate Stage Hepatocellular Carcinoma Classifications: the Reviewhttps://orcid.org/0000-0002-3429-3708ХайцманД. М.KhaitsmanD. M.

аспирант, врач отделения рентгенохирургических методов диагностики и лечения,

115478, Москва, Каширское шоссе, 24

24 Kashirskoye Highway, Moscow 115478

d.khaitsman@gmail.comhttps://orcid.org/0000-0002-4587-4153ПогребняковИ. В.PogrebnyakovI. V.

кандидат медицинских наук, и.о. заведующего отделением рентгенохирургических методов диагностики и лечения,

115478, Москва, Каширское шоссе, 24

24 Kashirskoye Highway, Moscow 115478

https://orcid.org/0000-0002-4006-3642ВиршкеЭ. Р.VirshkeE. R.

доктор медицинских наук, заведующий рентгенооперационным блоком отдела интервенционной радиологии,

115478, Москва, Каширское шоссе, 24

24 Kashirskoye Highway, Moscow 115478

https://orcid.org/0000-0002-5800-8684ТрофимовИ. А.TrofimovI. A.

врач по рентгенэндоваскулярным диагностике и лечению отделения рентгенохирургических методов диагностики и лечения,

115478, Москва, Каширское шоссе, 24

24 Kashirskoye Highway, Moscow 115478

https://orcid.org/0000-0002-6331-5611ФранцевД. Ю.FrantsevD. Yu.

кандидат медицинских наук, врач по рентгенэндоваскулярным диагностике и лечению отделения рентгенохирургических методов диагностики и лечения,

115478, Москва, Каширское шоссе, 24

24 Kashirskoye Highway, Moscow 115478

https://orcid.org/0000-0002-6323-511XДжанянИ. А.DzhanyanI. A.

врач отделения химиотерапии №17,

115478, Москва, Каширское шоссе, 24

24 Kashirskoye Highway, Moscow 115478

https://orcid.org/0000-0002-6244-4294БредерВ. В.BrederV. V.

доктор медицинских наук, ведущий научный сотрудник отделения химиотерапии №17,

115478, Москва, Каширское шоссе, 24

24 Kashirskoye Highway, Moscow 115478

https://orcid.org/0000-0001-7185-7165ДолгушинБ. И.DolgushinB. I.

академик РАН, доктор медицинских наук, профессор, заместитель директора по научной и лечебной работе  — директор НИИ КиЭР,

115478, Москва, Каширское шоссе, 24

24 Kashirskoye Highway, Moscow 115478

Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава РоссииРоссияN.N. Blokhin National Medical Research Center of OncologyRussian Federation202112042021415364Copyright © Хайцман Д.М., Погребняков И.В., Виршке Э.Р., Трофимов И.А., Францев Д.Ю., Джанян И.А., Бредер В.В., Долгушин Б.И., 20212021Хайцман Д.М., Погребняков И.В., Виршке Э.Р., Трофимов И.А., Францев Д.Ю., Джанян И.А., Бредер В.В., Долгушин Б.И.Khaitsman D.M., Pogrebnyakov I.V., Virshke E.R., Trofimov I.A., Frantsev D.Y., Dzhanyan I.A., Breder V.V., Dolgushin B.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncoradjournal.ru/jour/article/view/157

Заболеваемость гепатоцеллюлярной карценомой (ГЦК) остается пока высокой — данная нозология занимает пятое место в мире среди онкологических заболеваний. Подходы к лечению варьируются в зависимости от распространенности опухолевого процесса. Согласно классификации BCLC, пациентам со стадией В рекомендовано проведение трансартериальной химиоэмболизации (ТАХЭ), однако в эту группу входят пациенты с различной степенью внутрипеченочного распространения опухоли, а также с различным функциональным состоянием печени. Разрабатываются новые классификации, которые определяют тактику лечения и прогноз выживаемости, принимая во внимание гетерогенность данной группы больных. Целью настоящей работы является литературный обзор существующих классификаций и описание их прогностического значения. 

Hepatocellular carcinoma is the fifth most common cancer worldwide and the approaches to treatmentdiffer due to the stage of the disease. According to BCLC classification, B stage patients are recommendedto be underwent transarterial chemoembolization. However, BCLC B integrates patients with differentintrahepatic tumor burden and with different liver deterioration. There are many staging classifications thatdetermine the treatment and survival rates due to heterogeneity of this patient cohort. The aim of this studyis to review the existing ones and to describe their prognostic value.

гепатоцеллюлярная карциноматрансартериальная химиоэмболизацияклассификация BCLChepatocellular carcinomatransarterial chemoembolizationBCLC classificationReferencesFitzmaurice C, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level results from the global burden of disease study 2015. JAMA Oncol. 2017;3(12):1683-91. DOI: 10.1001/jamaoncol.2017.3055.Fitzmaurice C, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level results from the global burden of disease study 2015. JAMA Oncol. 2017;3(12):1683-91. DOI: 10.1001/jamaoncol.2017.3055.Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. In: Abdominal Radiology. Vol. 43, Springer New York LLC. 2018:13-25. DOI: 10.1007/s00261-017- 1209.Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. In: Abdominal Radiology. Vol. 43, Springer New York LLC. 2018:13-25. DOI: 10.1007/s00261-017- 1209.Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. Journal of Carcinogenesis. 2017;16:1-8. DOI: 10.4103/jcar.JCar_9_16.Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. Journal of Carcinogenesis. 2017;16:1-8. DOI: 10.4103/jcar.JCar_9_16.Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul J-L, et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma [Internet]. 2018 [cited 2020 May 23]. DOI: 10.1016/j.jhep.2018.03.019.Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul J-L, et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma [Internet]. 2018 [cited 2020 May 23]. DOI: 10.1016/j.jhep.2018.03.019.Benson AB, Abbott DE, Abrams TA, Anaya DA, Anders R, Brown D, et al. NCCN Guidelines Version 5.2020 Hepatobiliary Cancers [Internet]. 2020.Benson AB, Abbott DE, Abrams TA, Anaya DA, Anders R, Brown D, et al. NCCN Guidelines Version 5.2020 Hepatobiliary Cancers [Internet]. 2020.Breder VV, Balakhnin PV, Virshke ER, et al. Practical recommendations for drug therapy for paatients with hepatoccelular carcinoma. Practical recommendations RUSSCO. 2020;10(3s2):455-74. (In Russ.). DOI: 10.18027/2224-5057-2020-10-3s2-25.Breder VV, Balakhnin PV, Virshke ER, et al. Practical recommendations for drug therapy for paatients with hepatoccelular carcinoma. Practical recommendations RUSSCO. 2020;10(3s2):455-74. (In Russ.). DOI: 10.18027/2224-5057-2020-10-3s2-25.Piscaglia F, Ogasawara S. Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/ Risk Assessment. Liver Cancer. 2018;7:104-19. DOI: 10.1159/000485471.Piscaglia F, Ogasawara S. Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/ Risk Assessment. Liver Cancer. 2018;7:104-19. DOI: 10.1159/000485471.Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients with Hepatocellular Carcinoma. Gastroenterology. 2016;150:835-53. DOI: 10.1053/j.gastro.2015.12.041.Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients with Hepatocellular Carcinoma. Gastroenterology. 2016;150:835-53. DOI: 10.1053/j.gastro.2015.12.041.Comparative analysis of the modern staging systems of hepatocellular carcinoma — TNM / AJCC, CUPI, CLIP and BCLC from everyday clinical practice in Russia. Bulletin of Russian Oncological Scientific Center. 2016;(18):28-36. (In Russ.). DOI: 10.18027/2224.Comparative analysis of the modern staging systems of hepatocellular carcinoma — TNM / AJCC, CUPI, CLIP and BCLC from everyday clinical practice in Russia. Bulletin of Russian Oncological Scientific Center. 2016;(18):28-36. (In Russ.). DOI: 10.18027/2224.Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: Proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012;32(4):348-59. DOI: 10.1055/s-0032-1329906.Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: Proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012;32(4):348-59. DOI: 10.1055/s-0032-1329906.Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009 Jan;10(1):35-43. DOI: 10.1016/S1470-2045(08)70284-5.Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009 Jan;10(1):35-43. DOI: 10.1016/S1470-2045(08)70284-5.Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatology International. 2010;4:439-74. DOI: 10.1007/s12072-010-9165-7.Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatology International. 2010;4:439-74. DOI: 10.1007/s12072-010-9165-7.Ha Y, Shim JH, Kim SO, Kim KM, Lim YS, Lee HC. Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis. J Gastroenterol Hepatol. 2014;29(4):787-93. DOI: 10.1111/jgh.12452.Ha Y, Shim JH, Kim SO, Kim KM, Lim YS, Lee HC. Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis. J Gastroenterol Hepatol. 2014;29(4):787-93. DOI: 10.1111/jgh.12452.Giannini EG, Moscatelli A, Pellegatta G, Vitale A, Farinati F, Ciccarese F, et al. Application of the Intermediate-Stage Subclassification to Patients with Untreated Hepatocellular Carcinoma. Am J Gastroenterol. 2016 Jan 1;111(1):70-7. DOI: 10.1038/ajg.2015.389.Giannini EG, Moscatelli A, Pellegatta G, Vitale A, Farinati F, Ciccarese F, et al. Application of the Intermediate-Stage Subclassification to Patients with Untreated Hepatocellular Carcinoma. Am J Gastroenterol. 2016 Jan 1;111(1):70-7. DOI: 10.1038/ajg.2015.389.Weinmann A, Koch S, Sprinzl M, Kloeckner R, Schulze-Bergkamen H, Düber C, et al. Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients. Liver Int. 2015;35(2):591-600. DOI: 10.1111/liv.12696.Weinmann A, Koch S, Sprinzl M, Kloeckner R, Schulze-Bergkamen H, Düber C, et al. Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients. Liver Int. 2015;35(2):591-600. DOI: 10.1111/liv.12696.Ciria R, López-Cillero P, Gallardo AB, Cabrera J, Pleguezuelo M, Ayllón MD, et al. Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization. Eur J Surg Oncol. 2015 Sep 1;41(9):1153-61. DOI: 10.1016/j.ejso.2015.05.023.Ciria R, López-Cillero P, Gallardo AB, Cabrera J, Pleguezuelo M, Ayllón MD, et al. Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization. Eur J Surg Oncol. 2015 Sep 1;41(9):1153-61. DOI: 10.1016/j.ejso.2015.05.023.Liang L, Xing H, Zhang H, Zhong J, Li C, Lau WY, et al. Surgical resection versus transarterial chemoembolization for BCLC intermediate stage hepatocellular carcinoma: a systematic review and meta-analysis. HPB. 2018;20:110-9. DOI: 10.1016/j.hpb.2017.10.004.Liang L, Xing H, Zhang H, Zhong J, Li C, Lau WY, et al. Surgical resection versus transarterial chemoembolization for BCLC intermediate stage hepatocellular carcinoma: a systematic review and meta-analysis. HPB. 2018;20:110-9. DOI: 10.1016/j.hpb.2017.10.004.Ho EY, Cozen ML, Shen H, Lerrigo R, Trimble E, Ryan JC, et al. Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma. HPB. 2014 Aug 1;16(8):758-67. DOI: 10.1111/hpb.12214.Ho EY, Cozen ML, Shen H, Lerrigo R, Trimble E, Ryan JC, et al. Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma. HPB. 2014 Aug 1;16(8):758-67. DOI: 10.1111/hpb.12214.Yamakado K, Miyayama S, Hirota S, Mizunuma K, Nakamura K, Inaba Y, et al. Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child–Pugh grade correlated with prognosis after transarterial chemoembolization. Jpn J Radiol. 2014 Mar 11;32(5):260-5. DOI: 10.1111/jgh.12686.Yamakado K, Miyayama S, Hirota S, Mizunuma K, Nakamura K, Inaba Y, et al. Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child–Pugh grade correlated with prognosis after transarterial chemoembolization. Jpn J Radiol. 2014 Mar 11;32(5):260-5. DOI: 10.1111/jgh.12686.Wang J-H, Kee K-M, Lin C-Y, Hung C-H, Chen C-H, Lee C-M, et al. Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma. J Gastroenterol Hepatol [Internet]. 2015 Feb 1 [cited 2020 May 23];30(2):358-63. DOI: 10.1111/jgh.12686.Wang J-H, Kee K-M, Lin C-Y, Hung C-H, Chen C-H, Lee C-M, et al. Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma. J Gastroenterol Hepatol [Internet]. 2015 Feb 1 [cited 2020 May 23];30(2):358-63. DOI: 10.1111/jgh.12686.Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, et al. Validation of Kinki criteria, a modified substaging system, in patients with intermediate stage hepatocellular carcinoma. Dig Dis. 2016;34(6):671-8. DOI: 10.1159/000448834.Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, et al. Validation of Kinki criteria, a modified substaging system, in patients with intermediate stage hepatocellular carcinoma. Dig Dis. 2016;34(6):671-8. DOI: 10.1159/000448834.Kim JH, Shim JH, Lee HC, Sung K-B, Ko H-K, Ko G, et al. New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization. Liver Int [Internet]. 2017;37(12):1861-8. DOI: 10.1159/000448834.Kim JH, Shim JH, Lee HC, Sung K-B, Ko H-K, Ko G, et al. New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization. Liver Int [Internet]. 2017;37(12):1861-8. DOI: 10.1159/000448834.

The authors declare that there are no conflicts of interest present.